These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35842190)

  • 41. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Brunetti M
    Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
    Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
    Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
    Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
    BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-vascular endothelial growth factor for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Evans JR
    Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
    Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
    Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
    Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity.
    Hoppe C; Holt DG; Arnold BF; Thinda S; Padmanabhan SP; Oatts JT
    J AAPOS; 2022 Dec; 26(6):305.e1-305.e6. PubMed ID: 36265750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
    Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
    JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
    Klufas MA; Chan RV
    J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.
    Stahl A; Krohne TU; Eter N; Oberacher-Velten I; Guthoff R; Meltendorf S; Ehrt O; Aisenbrey S; Roider J; Gerding H; Jandeck C; Smith LEH; Walz JM;
    JAMA Pediatr; 2018 Mar; 172(3):278-286. PubMed ID: 29309486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treated Cases of Retinopathy of Prematurity in Germany: 10-Year Data from the Retina.net Retinopathy of Prematurity Registry.
    Pfeil JM; Barth T; Lagrèze WA; Lorenz B; Hufendiek K; Liegl R; Breuss H; Bemme S; Aisenbrey S; Glitz B; Süsskind D; Gabel-Pfisterer A; Skevas C; Krohne TU; Kakkassery V; Bründer MC; Engelmann K; Guthoff R; Walter P; Choritz L; Stahl A;
    Ophthalmol Retina; 2024 Jun; 8(6):579-589. PubMed ID: 38104929
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of Retinopathy of Prematurity Regression and Reactivation Using an Artificial Intelligence-Based Vascular Severity Score.
    Eilts SK; Pfeil JM; Poschkamp B; Krohne TU; Eter N; Barth T; Guthoff R; Lagrèze W; Grundel M; Bründer MC; Busch M; Kalpathy-Cramer J; Chiang MF; Chan RVP; Coyner AS; Ostmo S; Campbell JP; Stahl A;
    JAMA Netw Open; 2023 Jan; 6(1):e2251512. PubMed ID: 36656578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
    Kang HG; Kim TY; Han J; Han SH
    Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.
    Zhang H; Yang X; Zheng F; Wan S; Xu Y
    Ophthalmologica; 2023; 246(2):81-89. PubMed ID: 36709750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.